Comprehensive Market Analysis on Antisense RNAi Therapeutics Market projected to reach USD 14.3 Billion by 2030 | CAGR of 17.2% | Forecast period 2023-2030, published by MarketDigits

Antisense RNAi Therapeutics Market Scope:
Market size value in 2023 - USD 4.7 Billion
Market size value in 2030 - USD 1,268.5 Billion
CAGR (2023-2030) - 17.2%
Forecast Period - 2023-2030
Segments Covered - Technology, Route of Administration, Application And Region
Geographies Covered - North America, Europe, Asia Pacific, and Row
Sample of Companies Covered - Sarepta Therapeutics, Inc., Silence Therapeutics, Alnylam Pharmaceuticals, Inc., Astellas Pharma Inc., Benitec Biopharma Inc, Ionis Pharmaceuticals

Download Sample Pages-https://www.marketdigits.com/request/sample/4533

Browse in-depth TOC on Antisense RNAi Therapeutics Market
178-Tables
95-Figures
332-Pages

North America dominates the market for antisense RNAi therapeutics.
North America stands out as the dominating region in the global antisense RNAi therapeutics market, with the U.S. leading in consumption and market share. In this region, particularly the United States, the market is driven by research and development activities, a well-established biopharmaceutical sector, and favorable regulatory frameworks. The region benefits from a high level of healthcare infrastructure and significant investments in genomic research, creating a conducive environment for the growth of antisense RNAi therapeutics. Furthermore, strategic collaborations between industry players and research institutions contribute to the market's expansion in North America.
Asia Pacific region is witnessing a rise in demand for innovative therapeutic solutions, driven by the increasing prevalence of genetic disorders and chronic diseases. Countries like China and Japan are at the forefront of this market expansion, fueled by advancements in healthcare infrastructure, a large patient population, and a rapidly evolving biotechnology landscape. The Asia Pacific region also demonstrates a growing emphasis on personalized medicine and genomics research, further driving the adoption of antisense RNAi therapeutics.
Another noteworthy region is the Middle East and Africa, faces challenges such as limited financial resources, underdeveloped regulatory frameworks, and political instability. However, there are opportunities stemming from the region's increasing focus on healthcare infrastructure and a rising prevalence of genetic disorders.

Ask for Discount- https://www.marketdigits.com/request/discount/4533

Top Key Players Covered in the Report-
Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Astellas Pharma Inc., Benitec Biopharma Inc, Biogen, GSK plc, Ionis Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi, Sarepta Therapeutics, Inc., Silence Therapeutics and Others

For More Information - Inquire Now!
https://www.marketdigits.com/request/enquiry-before-buying/4533

Recent Developments-
In July 2023, Alnylam Pharmaceuticals has announced a partnership with Roche to jointly develop and commercialize zilebesiran, an investigational RNAi therapeutic for hypertension in Phase 2. The collaboration aims to disrupt the global hypertension treatment paradigm, aligning with Alnylam's P5x25 strategy for impactful advancements in the field.

https://industrytoday.co.uk/market-research-industry-today/emerging-trends-and-innovations-for-the-antisense-rnai-therapeutics-market-projected-to-reach-usd-143-billion-by-2030

MarketDigits
Email: sales@marketdigits.com

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

This release was published on openPR.